8-K: N2OFF Inc. Extends $250,000 Loan to MitoCareX Bio Ltd. Guaranteed by L.I.A. Pure Capital Ltd.

N2OFF, Inc. has entered into a loan agreement to provide $250,000 to MitoCareX Bio Ltd., with L.I.A. Pure Capital Ltd. guaranteeing the repayment.

Summary

• N2OFF, Inc. has agreed to loan $250,000 to MitoCareX Bio Ltd.
• The loan agreement was finalized on March 12, 2025.
• The loan accrues interest at an annual rate based on the Israel Tax Authority's guidelines for USD loans, which is currently the USD exchange rate fluctuation until the maturity date plus 3%.
• The loan term is six months, with both principal and accrued interest due at maturity.
• L.I.A. Pure Capital Ltd. is guaranteeing the repayment of the loan.
• If MitoCareX becomes a subsidiary of N2OFF, any outstanding loan amount will be deducted from future allocations to MitoCareX during the first year following the transaction.
• This loan aims to support MitoCareX's ongoing operational costs until the closing of a previously announced securities purchase and exchange agreement.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The loan provides short-term funding, but its success depends on the closing of a future transaction. There are inherent risks associated with lending to smaller companies.

Positives

• The loan is guaranteed by L.I.A. Pure Capital Ltd., reducing N2OFF's risk.
• The loan supports MitoCareX's operations, potentially facilitating the closing of the securities purchase and exchange agreement.
• The interest rate is based on a defined formula, providing clarity.

Negatives

• The loan represents an additional financial commitment for N2OFF.
• Repayment is dependent on MitoCareX's financial stability or the closing of the securities purchase agreement.
• The interest rate is variable, based on USD exchange rate fluctuations.

Risks

• MitoCareX may not be able to repay the loan if the securities purchase agreement does not close.
• Fluctuations in the USD exchange rate could impact the effective interest rate.
• There is a risk that L.I.A. Pure Capital Ltd. may not be able to fulfill its guarantee.

Future Outlook

The loan is intended to provide MitoCareX with financing until the closing of the securities purchase and exchange agreement. If the transaction closes, the loan amount will be deducted from future allocations to MitoCareX.

Industry Context

This loan agreement reflects a continued investment and financial support strategy by N2OFF towards MitoCareX, potentially indicating a strategic move to acquire or integrate MitoCareX into its operations. Such financial arrangements are common in the biotechnology and pharmaceutical industries to support research, development, and operational costs of smaller companies pending potential acquisitions or partnerships.

Comparison to Industry Standards

• Venture debt and convertible notes are common financing tools in the biotech industry, often used to bridge funding gaps before larger equity rounds or acquisitions.
• The interest rate structure, pegged to a benchmark plus a margin, is typical for loans of this nature, reflecting the risk profile of the borrower.
• Similar deals often include warrants or equity kickers to compensate lenders for the higher risk, which are not mentioned in this agreement.
• Companies like Oxford Finance and Silicon Valley Bank are active lenders in the biotech space, providing similar financing solutions to companies like MitoCareX.

Stakeholder Impact

• Shareholders of N2OFF are exposed to the risk of the loan not being repaid.
• MitoCareX benefits from the additional funding to continue its operations.
• Employees of MitoCareX benefit from the continued operation of the company.

Next Steps

• MitoCareX needs to utilize the loan to cover its ongoing costs and obligations.
• N2OFF needs to monitor MitoCareX's progress and the status of the securities purchase and exchange agreement.
• The parties need to work towards closing the securities purchase and exchange agreement.

Key Dates